NO

NovMetaPharma Co., Ltd.

Develops first-in-class drugs and supplements for metabolic and fibrotic diseases.

229500 | KO

Overview

Corporate Details

ISIN(s):
KR7229500004
LEI:
Country:
South Korea
Address:
서울특별시 강남구 언주로 727 13층 (논현동, 트리스빌딩), 강남구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NovMetaPharma Co., Ltd. is a biopharmaceutical company specializing in the research, development, and commercialization of first-in-class drugs for metabolic and fibrotic diseases. The company focuses on creating novel treatments with differentiated mechanisms to address significant unmet medical needs. Its core pipeline includes therapeutic candidates for conditions such as type 2 diabetes, obesity, chronic kidney disease, and fibrosis, with lead assets including Cyclo-Z and CHP. In addition to its primary focus on drug development, the company also develops health supplements and sells related raw materials.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-05-15 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.6 KB
2025-05-13 00:00
Regulatory News Service
특허권취득(자율공시)
Korean 4.8 KB
2025-04-29 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-03-31 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 170.5 KB
2025-03-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.3 KB
2025-03-24 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 20.3 KB
2025-03-24 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 22.1 KB
2025-03-14 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 361.6 KB
2025-03-13 00:00
Audit Report / Information
감사보고서제출
Korean 9.4 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 11.0 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 238.9 KB
2025-03-06 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 66.1 KB
2025-02-05 00:00
Regulatory News Service
특허권취득(자율공시)
Korean 5.6 KB
2024-12-20 00:00
Report Publication Announcement
기업설명회(IR)개최결과
Korean 6.7 KB
2024-12-17 00:00
Regulatory News Service
특허권취득(자율공시)
Korean 6.1 KB

Automate Your Workflow. Get a real-time feed of all NovMetaPharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NovMetaPharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NovMetaPharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America
AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America
ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK

Talk to a Data Expert

Have a question? We'll get back to you promptly.